2nd International Adalat® Symposium

New Therapy of Ischemic Heart Disease

  • Wilhelm Lochner
  • Wolfgang Braasch
  • Günther Kroneberg
Conference proceedings

Table of contents

  1. Front Matter
    Pages I-XVIII
  2. Introduction

    1. W. Lochner
      Pages 1-1
  3. Present Basis of Coronary Therapy

    1. W. Lochner
      Pages 2-10
  4. Chemistry and Experimental Pharmacology

    1. Front Matter
      Pages 11-11
    2. G. Kroneberg
      Pages 12-19
    3. F. Bossert
      Pages 20-26
    4. K. Patzschke, B. Duhm, W. Maul, H. Medenwald, L. A. Wegner
      Pages 27-32
    5. K. Schlossmann, H. Medenwald, H. Rosenkranz
      Pages 33-39
    6. K. Hagemann, W. Lochner, B. Niehues
      Pages 49-54
  5. Experimental Pharmacology

  6. Clinical Pharmacology

    1. Front Matter
      Pages 111-111
    2. H. Lydtin, G. Lohmöller, R. Lohmöller, H. Schmitz, I. Walter
      Pages 112-123
    3. F. A. Horster
      Pages 124-127
    4. P. F. Angelino, P. Tortore, R. Algranati
      Pages 128-139
    5. M. Van Den Brand, W. J. Remme, G. T. Meester, I. Tiggelaar-De Widt, R. De Ruiter, P. G. Hugenholtz
      Pages 145-153
  7. Clinical Pharmacological Efficacy

  8. Clinical Aspects: Hemodynamics, Onset and Duration

  9. Clinical Aspects: Special Studies

  10. Clinical Aspects: Proof of Clinical Efficacy

    1. Front Matter
      Pages 321-321

About these proceedings


The First Adalat Symposium held in Tokyo in 1973, presented important experimental and clinical results which had been collected in Europe and Japan with the new coronary therapeutic agent. The European scientists had an opportunity to discuss the problems and results personally with their Japanese colleagues. The Second Adalat Symposium was held in Amsterdam within a year with the purpose of bringing together mainly scientists within Europe. The results discussed in Tokyo have been extended and supplemented through additional experiences. Contributions in basic science are presented, but most important are those clinical studies, which support and extend proof of the drug's efficacy in humans. The editors wish to express their appreciation to all those responsible for contributing to this report and, in particular, to Dr. M. SPENGLER, Dr. F. EBNER and Dr. K. BRANDAU for their editorial help, and to Dr. W. BOTTGER for the preparation of the Subject Index. We hope that this publication will be a valuable contribution toward conveying information to physicians and scientists. DiisseldorfjWuppertal, Autumn 1975 W. LOCHNER' W BRAASCH' G. KRONEBERG Contents Introduction: W. LOCHNER Present Basis of Coronary Therapy: W. LOCHNER. With 11 Figures 2 Session I. Chemistry and Experimental Pharmacology (Chairmen: A. FLECKENSTEIN and K. LANDMARK) Pharmacology of Nifedipine: G. KRONEBERG. With 8 Figures 12 Discussion Remarks 19 The Chemistry of Nifedipine: F. BOSSERT. With 9 Figures 20 Pharmacokinetics of Adalat in Animal Experiments: K. PATZSCHKE, B.


Adalat angina pectoris chemistry circulation coronary artery disease diseases heart hemodynamics therapy

Editors and affiliations

  • Wilhelm Lochner
    • 1
  • Wolfgang Braasch
  • Günther Kroneberg
    • 2
  1. 1.Physiolog. Institut der UniversitätDüsseldorfFed. Rep. Germany
  2. 2.Bayer AG, Pharma Research DevelopmentFed. Rep. Germany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1975
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-540-07471-7
  • Online ISBN 978-3-642-66241-6
  • Buy this book on publisher's site